2019
Development and validation of a haematuria cancer risk score to identify patients at risk of harbouring cancer
Tan W, Ahmad A, Feber A, Mostafid H, Cresswell J, Fankhauser C, Waisbrod S, Hermanns T, Sasieni P, Kelly J, Khetrapal P, Baker H, Sridhar A, Lamb B, Ocampo F, McBain H, Baillie K, Middleton K, Watson D, Knight H, Maher S, Rane A, Pathmanathan B, Harmathova A, Hellawell G, Pelluri S, Pati J, Cossons A, Scott C, Madaan S, Bradfield S, Wakeford N, Dann A, Cook J, Cornwell M, Mills R, Thomas S, Reyner S, Vallejera G, Adeniran P, Masood S, Whotton N, Dent K, Pearson S, Hatton J, Newton M, Heeney E, Green K, Evans S, Rogers M, Gupwell K, Whiteley S, Brown A, McGrath J, Lunt N, Hill P, Sinclair A, Paredes‐Guerra A, Holbrook B, Ong E, Wardle H, Wilson D, Bayles A, Fennelly R, Tribbeck M, Ames K, Davies M, Taylor J, Edmunds E, Moore J, Mckinley S, Nolan T, Speed A, Tunnicliff A, Fossey G, Williams A, George M, Hutchins I, Einosas R, Richards A, Henderson A, Appleby B, Kehoe L, Gladwell L, Drakeley S, Davies J, Krishnan R, Roberts H, Main C, Jain S, Dumville J, Wilkinson N, Taylor J, Thomas F, Goulden K, Vinod C, Green E, Waymont C, Rogers J, Grant A, Carter V, Heap H, Lomas C, Cooke P, Scarratt L, Hodgkiss T, Johnstone D, Johnson J, Allsop J, Rothwell J, Connolly K, Cherian J, Ridgway S, Coulding M, Savill H, Mccormick J, Clark M, Collins G, Jewers K, Keith S, Bowen G, Hargreaves J, Riley K, Srirangam S, Rees A, Williams S, Dukes S, Goffe A, Dawson L, Mistry R, Chadwick J, Cocks S, Hull R, Loftus A, Baird Y, Moore S, Greenslade S, Margalef J, Chadbourn I, Harris M, Hicks J, Clitheroe P, Connolly S, Hodgkinson S, Haydock H, Sinclair A, Storr E, Cogley L, Natale S, Lovegrove W, Slack K, Nash D, Smith K, Walsh J, Guerdette A, Hill M, Payne D, Taylor B, Sinclair E, Perry M, Debbarma M, Hewitt D, Sriram R, Power A, Cannon J, Devereaux L, Thompson A, Atkinson K, Royle L, Madine J, MacLean K, Sarpong R, Brew‐Graves C, Williams N. Development and validation of a haematuria cancer risk score to identify patients at risk of harbouring cancer. Journal Of Internal Medicine 2019, 285: 436-445. PMID: 30521125, PMCID: PMC6446724, DOI: 10.1111/joim.12868.Peer-Reviewed Original ResearchConceptsCancer risk scoreNational Institute for Health and Clinical Excellence guidelinesRisk scoreInvestigation of haematuriaPhysician decision-makingAge-specific thresholdsValidation cohortExcellence guidelinesUK hospitalsAmerican Urological Association guidelinesNational guidelinesImprove patientNo significant overfittingImprove patient selectionUpper tract cancerLack of consensusAssociation guidelinesSmoking historySwiss patientsCohortPatient ageDevelopment cohortPatient selectionGuidelinesHaematuria
2018
Who Should Be Investigated for Haematuria? Results of a Contemporary Prospective Observational Study of 3556 Patients
Tan W, Feber A, Sarpong R, Khetrapal P, Rodney S, Jalil R, Mostafid H, Cresswell J, Hicks J, Rane A, Henderson A, Watson D, Cherian J, Williams N, Brew-Graves C, Kelly J, collaborators O. Who Should Be Investigated for Haematuria? Results of a Contemporary Prospective Observational Study of 3556 Patients. European Urology 2018, 74: 10-14. PMID: 29653885, DOI: 10.1016/j.eururo.2018.03.008.Peer-Reviewed Original ResearchConceptsUrinary tract cancerIncidence of urinary tract cancerInvestigation of haematuriaRisk of urinary tract cancerClinically significant cancerDiagnosis of urinary tract cancerHigh-risk cancerProspective observational studyIncidence of cancerSignificant cancerAge thresholdBladder cancerSmoking historyVisible bloodOlder patientsHaematuriaMale genderConsensus recommendationsPatientsObservational studyCancerPatient preferencesCancer diagnosisLack of consensusAge
2017
UroMark—a urinary biomarker assay for the detection of bladder cancer
Feber A, Dhami P, Dong L, de Winter P, Tan W, Martínez-Fernández M, Paul D, Hynes-Allen A, Rezaee S, Gurung P, Rodney S, Mehmood A, Villacampa F, de la Rosa F, Jameson C, Cheng K, Zeegers M, Bryan R, James N, Paramio J, Freeman A, Beck S, Kelly J. UroMark—a urinary biomarker assay for the detection of bladder cancer. Clinical Epigenetics 2017, 9: 8. PMID: 28163793, PMCID: PMC5282868, DOI: 10.1186/s13148-016-0303-5.Peer-Reviewed Original ResearchConceptsDetection of bladder cancerEpigenetic alterationsSequencing assayNovel high-throughputBladder cancerBackgroundBladder cancerNext-generation sequencing assayUrinary biomarkersDNA methylationMuscle-invasive bladder cancerUrinary biomarker assaysSediment DNAAnalysis pipelineVoided urine samplesDetection of BCPrimary BCHigh-throughputCystoscopic examinationVoided urineDNAIndependent cohortAssayBiomarker panelDiagnosed BCCancer
2010
[Risk factors of novel severe influenza A(H1N1) with concurrent adult respiratory distress syndrome].
Dai B, Kang J, Wang Z, Kong D, Tan W, Zhao H. [Risk factors of novel severe influenza A(H1N1) with concurrent adult respiratory distress syndrome]. National Medical Journal Of China 2010, 90: 2392-5. PMID: 21092507.Peer-Reviewed Original ResearchConceptsAdult respiratory distress syndromeT lymphocyte subsetsSevere influenza AMultivariate logistic regression analysisNon-ARDS groupInfluenza ANon-smoking groupLogistic regression analysisStatistically significant differenceRisk factorsIncidence of adult respiratory distress syndromeAdult respiratory distress syndrome patientsNovel influenza APatient lymphocyte countsRespiratory distress syndromeSignificant differenceControlled clinical trialsLactate dehydrogenaseRegression analysisDistress syndromeLymphocyte countClinical featuresRetrospective analysisClinical trialsH1N1